ライフサイエンスコーパス: platelet transfusion

1 at 0.25 to 4 hours and 16 to 32 hours after platelet transfusion.

2 ransferred by bone marrow transplantation or platelet transfusion.

3 the chances of many of the complications of platelet transfusion.

4 he last dose of cyclophosphamide to the last platelet transfusion.

5 bone marrow failure, requiring prophylactic platelet transfusion.

6 ical problem for which the main treatment is platelet transfusion.

7 , profound thrombocytopenia recurred despite platelet transfusion.

8 ho failed to achieve an adequate response to platelet transfusion.

9 Only 2 patients required more than one platelet transfusion.

10 vention, and management of refractoriness to platelet transfusion.

11 nulocytopenic fever, and no patient required platelet transfusion.

12 ted adverse immune reactions associated with platelet transfusion.

13 d each patient's platelet count responded to platelet transfusion.

14 ing episodes, which increases the demand for platelet transfusion.

15 erience decreased clinical responsiveness to platelet transfusion.

16 basis of platelet function for prophylactic platelet transfusion.

17 Forty-nine patients (88%) did not require platelet transfusion.

18 uma resuscitation has shifted toward liberal platelet transfusions.

19 logy patients who received 6031 prophylactic platelet transfusions.

20 t approach for managing ABO compatibility in platelet transfusions.

21 let counts of less than 10 x 10(9) per L; or platelet transfusions.

22 cal trials of the optimal timing and dose of platelet transfusions.

23 usion practices, and adverse consequences of platelet transfusions.

24 h aplastic anemia refractory to random donor platelet transfusions.

25 life-threatening bleeding episodes requiring platelet transfusions.

26 d significantly improve the effectiveness of platelet transfusions.

27 adverse event was recorded during autologous platelet transfusions.

28 se myelosuppression, and reduce the need for platelet transfusions.

29 emotherapy acquire thrombocytopenia and need platelet transfusions.

30 treatment with immunosuppressive agents and platelet transfusions.

31 ere thrombocytopenia and reduce the need for platelet transfusions.

32 quent incorporation of cytokines and RBC and platelet transfusions.

33 Peripheral blood counts and platelet transfusions.

34 ry interruption of abciximab infusions or to platelet transfusions.

35 red more days of intravenous antibiotics and platelet transfusions.

36 atients, both in the PIXY321 group, required platelet transfusions.

37 tions, schedule alterations, or the need for platelet transfusions.

38 hospitalization, and seven patients required platelet transfusions.

39 of severe thrombocytopenia and the need for platelet transfusions.

40 nic hematology/oncology patients in spite of platelet transfusions.

41 tients receiving prophylactic or therapeutic platelet transfusions.

42 (3) control), average number of days to next platelet transfusion (1.9 PCT versus 2.4 control), and n

43 BSC patients received fewer platelet transfusions: 10 versus 19 (P = .015).

44 surgery was associated with a higher risk of platelet transfusion (22.7% [5 of 22] vs 6.4% [12 of 187

45 significantly decreased the requirement for platelet transfusions; 27 of 40 (68%) patients who recei

46 mination; and there was inappropriate use of platelet transfusions (41 with mild or moderate disease)

47 10(9)/L (16 v 23 days; P = .02), and days of platelet transfusions (6 v 10; P < .001).

48 (1.9 PCT versus 2.4 control), and number of platelet transfusions (8.4 PCT versus 6.2 control) were

49 These patients may be refractory to platelet transfusion, a condition that would increase th

50 Platelet transfusion after acute spontaneous primary int

51 Keywords included platelet transfusion, alloimmunization, hemorrhage, thre

52 ith severe thrombocytopenia receive repeated platelet transfusions, although evidence of their clinic

53 23 (24%) participants assigned to platelet transfusion and 16 (17%) assigned to standard c

54 97 participants were randomly assigned to platelet transfusion and 93 to standard care.

55 opments in the area of ABO compatibility and platelet transfusion and examines the risks and benefits

56 ed for the continued use of prophylaxis with platelet transfusion and show the benefit of such prophy

57 It will also briefly address platelet transfusion and the role of glycans in the clea

58 The median time to last platelet transfusion and time to 0.5 x 10(9) neutrophils

59 ia occurred in 32% of patients; 63% received platelet transfusions and 58% required RBCs.

60 Our data validate HLAMatchmaker for platelet transfusions and demonstrate its potential to r

61 Decreased number of red blood cell and platelet transfusions and in some cases transfusion inde

62 Number of platelet transfusions and incidence of IVH.

63 y to the above treatment plus daily multiple platelet transfusions and IV immunoglobulin.

64 strategy to minimise the risks of allogeneic platelet transfusions and provide a long-lasting supply

65 ematologic malignancy, resulting in frequent platelet transfusions and significant resource consumpti

66 ant candidates often leads to multiple blood/platelet transfusions and subsequent development of allo

67 Despite an increase in observed bleeding, platelet transfusion, and surgical re-exploration for bl

68 h an increased risk of early RBC, plasma and platelet transfusions, and fibrinolysis.

69 gorithm reduces red blood cell transfusions, platelet transfusions, and major bleeding following card

70 erienced more frequent hospitalization, more platelet transfusions, and more missed doses of chemothe

71 d were platelet increments, interval between platelet transfusions, and platelet refractoriness.

72 ion, year of therapy, sex, refractoriness to platelet transfusions, and previous treatment with andro

73 orrelated with low preoperative PLT, massive platelet transfusions, and re-transplantation.

74 latelet count of 17,000/mm3 despite repeated platelet transfusions, and splenectomy was done.

75 marrow chimera, mast cell-deficient animals, platelets transfusion, and bone marrow dendritic cells (

76 Platelet transfusions are a crucial component of support

77 Low-dose prophylactic platelet transfusions are as effective in the prevention

78 Platelet transfusions are associated with higher odds of

79 Platelet transfusions are life-saving treatments for man

80 onents such as fresh frozen plasma (FFP) and platelet transfusions are limited.

81 Platelet transfusions are now the cornerstone for treati

82 Platelet transfusions are often a life-saving interventi

83 Platelet transfusions are required to prevent the potent

84 Red blood cell (RBC) and platelet transfusions are the mainstays of therapy, but

85 ting both the safety and efficacy of liberal platelet transfusions are warranted.

86 row transplant patients who require multiple platelet transfusions as a consequence of post-transplan

87 nia starting on day 15 of the first cycle or platelet transfusion at any time during the 4-cycle trea

88 Prophylactic platelet transfusion at defined platelet count threshold

89 ntation at experienced centers may receive a platelet transfusion at the first sign of bleeding, rath

90 cers or solid tumors to receive prophylactic platelet transfusions at a low dose, a medium dose, or a

91 Patients refractory to platelet transfusions because of alloimmunization requir

92 or protocol violation (n = 62) or received a platelet transfusion before treatment was discontinued a

93 The primary end point was the avoidance of a platelet transfusion before, during, and up to 7 days af

94 half to twice the usual dose of 2.2 x 10(11) platelets/transfusion/body surface area (BSA) do not aff

95 half to twice the usual dose of 2.2 x 10(11) platelets/transfusion/BSA have no affect on WHO bleeding

96 with aspirin alone was associated with more platelet transfusion but similar degree of bleeding; in

97 8(+) T cells are required for priming during platelet transfusion, but only CD8(+) T cells are requir

98 However, platelet transfusion can transmit infections and trigger

99 Platelet transfusion cannot be recommended for this indi

100 10(9)/L has become accepted for prophylactic platelet transfusions, care should be taken to ensure th

101 atelet counts and thereby delay time to next platelet transfusion compared to routinely available pla

102 n nonmyeloablative transplants, 23% required platelet transfusions compared with 100% among patients

103 The estimated average 60-day platelet transfusion cost per patient was $4,000 for aut

104 m cells (PBSC) had faster recovery and fewer platelet transfusion days than recipients of bone marrow

105 predicted longer periods of neutropenia and platelet transfusion dependence (P <or=.03).

106 er L; had 10-50% bone-marrow blasts; or were platelet transfusion dependent were randomly assigned (2

107 contaminated platelets are a major hazard of platelet transfusion despite recent interventions.

108 Refractoriness to platelet transfusions developed in 27% of the patients.

109 icant clinical factors and thrombocytopenia, platelet transfusions did not have a significant effect

110 did not correlate with the risk for IVH, and platelet transfusions did not reduce this risk.

111 was hematologic, with two patients requiring platelet transfusions due to thrombocytopenia and two re

112 Patients in group A received platelet transfusions during implantation.

113 P guided by CCA and utilizes less plasma and platelet transfusions during the early phase of resuscit

114 For preoperative PLT, platelet transfusions during the operation, re-transplan

115 t it is unclear whether these factors impact platelet transfusion efficacy on clinical bleeding.

116 Untreated platelet transfusions elicited strong IgG responses that

117 The AABB suggests platelet transfusion for patients having bypass who exhi

118 MMENDATION 2: The AABB suggests prophylactic platelet transfusion for patients having elective centra

119 MMENDATION 3: The AABB suggests prophylactic platelet transfusion for patients having elective diagno

120 MMENDATION 4: The AABB suggests prophylactic platelet transfusion for patients having major elective

121 6: The AABB cannot recommend for or against platelet transfusion for patients receiving antiplatelet

122 AABB recommends against routine prophylactic platelet transfusion for patients who are nonthrombocyto

123 o the < or = 10,000/microL arm received more platelet transfusions for bleeding [one (0, 2) v zero (0

124 Days of platelet support and number of platelet transfusions for patients with ALI were not sig

125 n the < or = 20,000/microL arm received more platelet transfusions for prophylactic indications [10 (

126 ons also induced tolerance to subsequent STD platelet transfusions from the same donor (82% acceptanc

127 We performed secondary analyses of platelet transfusions given in the prospective randomize

128 Nevertheless, the total number of platelet transfusions given to patients on the < or = 20

129 d high vs. medium), but the median number of platelet transfusions given was significantly higher in

130 or dependence at 3 months were higher in the platelet transfusion group than in the standard care gro

131 eline updates and replaces the previous ASCO platelet transfusion guideline published initially in 20

132 these questions in order to provide optimal platelet transfusion guidelines.

133 40 (42%) participants who received platelet transfusion had a serious adverse event during

134 n a life-saving intervention, and the use of platelet transfusions has been increasing.

135 both the blood platelet counts that prompt a platelet transfusion (i.e. trigger) in various clinical

136 16 320 patient-days on or after their first platelet transfusion in 1077 adult patients enrolled in

137 ding from childhood, requiring >/=1 blood or platelet transfusion in 78% of cases.

138 veloped this guideline on appropriate use of platelet transfusion in adult patients.

139 Other recommendations address platelet transfusion in patients with hematologic malign

140 rovide evidence-based guidance on the use of platelet transfusion in people with cancer.

141 levated by thrombocytopenia and decreased by platelet transfusion in septic mice.

142 ne Guidelines (the use of leukoreduction and platelet transfusion in solid tumors or chronic, stable

143 rehospital use of iron or erythropoietin and platelet transfusion in the ICU were independently assoc

144 development of evidence-based protocols for platelet transfusion in the newborn and stimulate contin

145 change to a previous recommendation involved platelet transfusion in the setting of hematopoietic ste

146 The need for platelet transfusion in this group was reduced from 75%

147 Therefore, the precise role and triggers for platelet transfusion in trauma have yet to be fully char

148 spective studies show that early high-volume platelet transfusion in trauma may be associated with si

149 the current evidence for the use of FFP and platelet transfusions in critically ill patients.

150 There is little consensus on optimal platelet transfusions in either civilian or military pra

151 aberrant activity in trauma and the role of platelet transfusions in exsanguinating haemorrhage.

152 The need for platelet transfusions in four cycles was significantly l

153 Platelet transfusions in HIT were associated with higher

154 riability in use of allogeneic RBC, FFP, and platelet transfusions in patients undergoing major nonca

155 etic growth factor, in reducing the need for platelet transfusions in patients who undergo dose-inten

156 associated thrombocytopenia and the need for platelet transfusions in patients who undergo dose-inten

157 Eltrombopag reduced the need for platelet transfusions in patients with chronic liver dis

158 als compared different doses of prophylactic platelet transfusions in patients with haematological ma

159 ng platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia

160 sol treatment to prevent alloimmunization by platelet transfusions in rats.

161 and may lead to decreased intervals between platelet transfusions in thrombocytopenic patients.

162 ilable on risks and benefits associated with platelet transfusions in thrombotic thrombocytopenic pur

163 Platelet transfusions in TTP were associated with higher

164 ation, fever, bleeding, increasing number of platelet transfusions, increasing weight, at least 2 pre

165 Platelet transfusion increments were assessed at 0.25 to

166 group (P = .07) and the median time to reach platelet transfusion independence in the PIXY321 group w

167 00/microL was 15 days and the median time to platelet transfusion independence was 16 days.

168 neutrophil count of 0.5 x 10(9) cells/L and platelet transfusion independence were 17 and 16 days, r

169 lasts were < 5% with neutrophil recovery and platelet transfusion independence) that lasted a median

170 emission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously

171 Duration of platelet transfusion independence, duration of response,

172 n the two agents with respect to the time to platelet transfusion independence.

173 cytopenia was common, with failure to become platelet-transfusion independent in nine patients.

174 ibodies in refractory thrombocytopenia (post platelet transfusion), indicating that the level of fuco

175 atelet preparations, the use of prophylactic platelet transfusions, indications for transfusion in se

176 Herein, we perform a mechanistic analysis of platelet transfusion-induced BMT rejection and report th

177 In addition, allogeneic platelet transfusions into SCID mice with established CD

178 Poor response to platelet transfusion is a clinically and financially sig

179 e of ABO blood group system compatibility in platelet transfusion is a subject of ongoing debate.

180 Platelet transfusion is a very common lifesaving medical

181 Prophylactic platelet transfusion is not necessary in children with p

182 Platelet transfusion is often used to restore hemostasis

183 t a 10,000/microL threshold for prophylactic platelet transfusion is safe and effective in uncomplica

184 Platelet transfusion is the most commonly used therapy b

185 platelet donors on patient outcome following platelet transfusion is unknown.

186 go lumbar puncture (LP) without prophylactic platelet transfusion is unknown.

187 e the evidence for a benefit of prophylactic platelet transfusions is weak and controversial.

188 nventionally described as "refractoriness to platelet transfusions," is defined by an unsatisfactory

189 fetal blood sampling (FBS) and intrauterine platelet transfusions (IUPT), as well as weekly maternal

190 standard (</=10 x 109/L), but required more platelet transfusions (low-quality evidence).

191 r platelets in septic shock and suggest that platelet transfusion may be effective in treating severe

192 This approach to platelet transfusion may be particularly important when

193 g allogeneic SCT or chemotherapy and because platelet transfusions may not prevent bleeding, other ri

194 al age, 28.2 [2.9] weeks), 231 received 1002 platelet transfusions (mean [SD], 4.3 [6.0] per infant;

195 Nine patients no longer needed platelet transfusions (median increase in platelet count

196 While platelet transfusion might be indicated in patients with

197 In a dog platelet transfusion model, we have evaluated other meth

198 5) was seen over six cycles after autologous platelet transfusions (n=63).

199 ny patients having an inadequate response to platelet transfusions, new strategies are needed to trea

200 donors increases when one antigen mismatched platelet transfusions (OAMPT) are considered, transfusio

201 The effect of platelet transfusions on IGF-1R was explored.

202 3.9), septicemia (OR, 1.8; 95% CI, 1.2-2.6), platelet transfusion (OR, 6.4; 95% CI, 3.2-12.4), and re

203 antibody positivity, an increasing number of platelet transfusions, or receiving heparin or amphoteri

204 as superior to platelet count for predicting platelet transfusion (P < 0.001); and LY-30 (rate of amp

205 ted with rhIL-11 at 25 micrograms/kg avoided platelet transfusions (P = .23).

206 ith fewer patients (P =.014) receiving fewer platelet transfusions (P =.001) than patients receiving

207 ts (P =.016), a lower duration of pretherapy platelet transfusions (P =.013), and higher pretherapy p

208 and there exists a significant variation in platelet transfusion practice between centers.

209 t Sample to evaluate the current in-hospital platelet transfusion practices and their association wit

210 yeloablative therapy, controversies surround platelet transfusion practices.

211 sure to alloantigens during transplantation, platelet transfusion primes alloimmunity but does not st

212 Platelet transfusions provide transient benefit and are

213 Platelet transfusion provides an important therapeutic i

214 Allogenic platelet transfusions (PT) are administered to treat exc

215 Overall FFP and platelet transfusion rates were 8.9% and 3.8%, respectiv

216 has been used as a trigger for prophylactic platelet transfusions rather than the morning platelet c

217 e factors, preoperative PLT, intra-operative platelet transfusions, re-transplantation, and early rej

218 0(9)/L or more platelets or in the number of platelet transfusions received.

219 atients receiving red blood cells or plasma, platelet transfusion recipients are at a greater risk fo

220 ess ABH antigens, which can adversely effect platelet transfusion recovery and survival in ABH-incomp

221 g. neonatal allo-immune thrombocytopenia and platelet transfusion refractoriness) the causative idiot

222 Some will exhibit platelet transfusion refractoriness, defined as inapprop

223 s technique has not been widely described in platelet transfusion refractory bone marrow transplant p

224 0.98; P=0.02; number needed to treat, 24.7), platelet transfusion (relative risk, 0.77; 95% confidenc

225 e of the side effects that could result from platelet transfusions remain under investigation.

226 data are the highest rate of acceptance for platelet transfusions reported in either animals or man.

227 11 significantly reduced the total number of platelet transfusions required in the assessable subgrou

228 bin III and protein C and an increase in the platelet transfusion requirement.

229 e duration of severe thrombocytopenia or the platelet transfusion requirement.

230 Red blood cell (RBC) and platelet transfusion requirements in patients given nonm

231 tropenia, incidences of febrile neutropenia, platelet transfusion requirements, and numbers of platel

232 The preoperative PLT, intra-operative platelet transfusion requirements, cross-match, recipien

233 creased platelet counts, and ten had reduced platelet transfusion requirements.

234 platelet levels and a resultant decrease in platelet transfusion requirements.

235 nd the only significant predictor of RBC and platelet transfusion requirements.

236 Platelet transfusion seems inferior to standard care for

237 rce utilization in order to identify optimal platelet transfusion strategies.

238 e the risk-benefit ratio of a liberal FFP or platelet transfusion strategy for critically ill patient

239 evaluating a restrictive vs. liberal FFP or platelet transfusion strategy for nonbleeding patients i

240 nd thrombopoiesis and to develop a potential platelet transfusion strategy that is not dependent upon

241 results of a therapeutic vs. a prophylactic platelet-transfusion strategy in acute myeloblastic leuk

242 Platelet transfusion studies demonstrate that platelet-d

243 Bone marrow transplantation and platelet transfusion studies demonstrated that platelet

244 Despite the reliance on platelet transfusion support in patients receiving myelo

245 wing within the screening period of 4 weeks: platelet transfusion, symptomatic bleeding, or platelet

246 For platelet transfusion, the American Society of Clinical O

247 the 1272 patients who received at least one platelet transfusion, the primary end point was observed

248 Evidence-based guidelines for platelet transfusion therapy in these patients are yet t

249 Currently platelet transfusion therapy is limited by several conce

250 lection in the 1960s laid the groundwork for platelet transfusion therapy on a scale not previously p

251 fication" approach enabled much wider use of platelet transfusion therapy until alternative means of

252 elets, this strategy may be a substitute for platelet transfusion therapy.

253 let transfusion requirements, and numbers of platelet transfusions; they also received induction chem

254 Specific platelet transfusion thresholds are based on the presenc

255 tion trial comparing two common prophylactic platelet transfusion thresholds in patients undergoing i

256 ly available data regarding neonatal RBC and platelet transfusion thresholds, as well as the potentia

257 We conducted a trial of prophylactic platelet transfusions to evaluate the effect of platelet

258 al platelet count threshold for prophylactic platelet transfusions to minimize bleeding, platelet use

259 The effectiveness of platelet transfusions to prevent bleeding in patients wi

260 that US neonatologists frequently administer platelet transfusions to VLBW infants with mild to moder

261 Platelet transfusions total >2.17 million apheresis-equi

262 A platelet transfusion trigger of </= 5 x 10(3)/muL may be

263 t a dose of 50 micrograms/kg did not require platelet transfusions versus 1 of 27 (4%) patients who r

264 east 2 days before surgery, the incidence of platelet transfusion was 12.4% (24 of 193) in the ticagr

265 A platelet transfusion was avoided in 104 of 145 patients

266 h thrombocytopenia (PCT, <100000/muL) when a platelet transfusion was given compared with 113 of 190

267 t-days (59.5%) with thrombocytopenia when no platelet transfusion was given.

268 eeding classifications, but the incidence of platelet transfusion was higher in the ticagrelor group

269 The incidence of platelet transfusions was 46%, 36%, and 69%, respectivel

270 whether a policy of not giving prophylactic platelet transfusions was as effective and safe as a pol

271 The incidence of bleeding events and platelet transfusions was less common among patients who

272 r insertion, and apheresis and a median of 9 platelet transfusions was required during hematopoietic

273 A median of 2 platelet transfusions was required for stem cell mobiliz

274 teria for 8 consecutive weeks independent of platelet transfusions) was achieved by 19 patients (46%)

275 Mean INR and platelet triggers for FFP and platelet transfusions were 1.9 +/- 1.3 and 60000 +/- 440

276 nt difference in the number of days on which platelet transfusions were administered among the 3 grou

277 adjusted odds ratios (adjOR) associated with platelet transfusions were calculated.

278 Until recently, prophylactic platelet transfusions were commonly given at a trigger o

279 Platelet transfusions were given in 16 pregnancies.

280 During that period, platelet transfusions were given on 35 of 53 days (66.0%

281 A large proportion of platelet transfusions were given to VLBW infants with PC

282 s, duration of thrombocytopenia, or need for platelet transfusions were observed with PIXY321 versus

283 Platelet transfusions were reported in 10.1% TTP, 7.1% H

284 No red blood cell or platelet transfusions were required, and no complication

285 Ever since platelet transfusions were shown to reduce mortality fro

286 Mean platelet transfusions were significantly decreased from

287 Preoperative need for red blood cell and platelet transfusions were the most significant risk fac

288 to receive, or not to receive, prophylactic platelet transfusions when morning platelet counts were

289 tle information is available on the value of platelet transfusion where the absolute count is less th

290 e recent research on the use of prophylactic platelet transfusions, which is a topic that still provo

291 platelet count of more than 20,000 required platelet transfusions while receiving therapy.

292 e procedures are established indications for platelet transfusions, while the evidence for a benefit

293 body-mediated ITP is resistant to allogeneic platelet transfusions, while the T-cell-mediated form of

294 When indicated, platelet transfusion will raise the platelet count to sa

295 dose and the threshold at which prophylactic platelet transfusions will be most effective.

296 We aimed to investigate whether platelet transfusion with standard care, compared with s

297 9) per L) or grade 4 thrombocytopenia before platelet transfusion, with 25 x 10(9) platelets per L or

298 e either standard care or standard care with platelet transfusion within 90 min of diagnostic brain i

299 101 of 530 participants became refractory to platelet transfusions without evidence of HLA or human p

300 ization, and management of refractoriness to platelet transfusion ( www.asco.org/supportive-care-guid